A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Obesity and Cardiovascular Risk
In brief
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Key facts
- Study ID
- NCT07656727
- Run by
- BioAge Labs, Inc.
- People needed
- 160
- Starts
- 2026-06-11
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Site 105 — San Juan, Puerto Rico (enrolling)
- Site 115 — Peoria, Arizona, United States (enrolling)
- Site 110 — Tucson, Arizona, United States (enrolling)
- Site 100 — Rogers, Arkansas, United States (enrolling)
- Site 109 — Maitland, Florida, United States (enrolling)
- Site 102 — Miami, Florida, United States (enrolling)
- Site 104 — Port Orange, Florida, United States (enrolling)
- Site 108 — Chandler, Arizona, United States (enrolling)
- Site 106 — Rockville, Maryland, United States (enrolling)
- Site 113 — Kansas City, Missouri, United States (enrolling)
- Site 112 — Austin, Texas, United States (enrolling)
- Site 101 — San Antonio, Texas, United States (enrolling)
- Site 103 — Lexington, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.